Metastatic Tumor Research and Outcomes Network

Study at a glance

From the registry record, last updated by the sponsor on 6 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title

Metastatic Tumor Research and Outcome Network A Multicenter Prospective Registry for the Management and Outcome of Metastatic Spine Tumors

ClinicalTrials.gov ID

NCT02830451

Acronym / sponsor ID

MTRON / MTRON

Conditions

Metastatic Spine Tumor

Keywords

Registry, Spine, Surgery, Medical Oncology, Radiation Oncology, Neoplasms, Metastasis, Chemotherapy

Study type

Observational

Recruitment status

Completed

Enrolment

2,417 participants (actual)

Lead sponsor

AO Innovation Translation CenterUniversity, hospital or other

Collaborators

AO Foundation, AO Spine

Study start

15 Nov 2017 (actual)

Primary completion

18 Aug 2026 (actual)

Study completion

18 Aug 2026 (actual)

First posted

12 Jul 2016 (estimated)

Results

Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Study design

Observational model

Case only

Time perspective

Prospective

Target follow-up

5 Years

Who may qualify

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Age groups

Adult, Older adult

Study population

Patient diagnosed with a metastatic tumor of the spine.

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Primary outcome

1. Patient details

   Time frame: collected at baseline

   The following patient data will be collected: * gender, year of birth, height, weight, race * work status, education level, marital status * smoking, alcohol and recreational drug use * medication use * nutrition and vitamin intake * presence of osteoporosis * comorbidities according to the Charlson Comorbidity Index - CCI

2. Tumor details

   Time frame: collected at baseline, first prospective treatment and follow-up

   Primary cancer * Site of the primary cancer * Year of diagnosis * Status of the tumor (removed completely, partially, or not removed) * Signs of local control or tumor progression * Tumor subtype * Tumor markers Spine metastases * Date of initial diagnosis of spine metastases * Identification of index target * Vertebral location (i.e., C1, T3-T5, etc.) * Details of spine metastases and other metastases, if any * Activity of systemic metastases * Local control of metastatic tumor * Presence of pathologic fracture * Radiographic evidence of new spine metastatic disease

3. Symptoms

   Time frame: collected at baseline, first prospective treatment and follow-up

   For patients with metastatic spine tumor, it is important to understand the occurrence, location, and type of pain patients have at baseline and at follow-up visits. Pain symptoms assessed by the physician will therefore be collected in addition to the pain specific PROs. Bowel and bladder function will be assessed by the physician.

4. Treatment details - previous treatment of the index of the spine

   Time frame: Collected at baseline

   If the patient had previous treatment (surgery, radiation or systemic oncologic therapy) for the index target, the following information about the previous treatment will be collected at baseline: * Type(s) of treatment * Date(s) of treatment * Treated vertebrae level(s) * Procedure details * Hospital/center where the treatment was administered * ASIA impairment scale (applies only to previous surgical patients)

5. Imaging information

   Time frame: collected at baseline, first prospective treatment, discharge and at follow-up.

   Skeletal muscle and adipose tissue measurements will be made from CT scans. One transverse CT image of the inferior surface of L3 will be assessed by an independent assessor to calculate the visceral fat area to subcutaneous fat ratio (VFA/SFA ratio). This measurement will only be collected if the CT scan is according to standard of care and the method is described in a separate imaging manual. Additional CT scans will not be performed for this Registry. Imaging is critical to select the biopsy technique and for disease diagnosis. Follow-up imaging also plays an important role in monitoring disease status. Imaging data will be collected to serve as a data repository, so that images may be more easily retrieved later if necessary. Imaging data * Image type (e.g. MRI, CT, PET, etc.) * Date taken * Name of institution storing image

6. Patient reported outcomes - Euroqol EQ-5D-3L / - EQ-5D VAS

   Time frame: collected at baseline, first prospective treatment, discharge and at follow-up.

   The EQ-5D-3L descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results into a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale where the endpoints are labelled 'Best imaginable health state' and 'Worst imaginable health state'. The VAS can be used as a quantitative measure of health outcome that reflects the patient's own judgement.

7. Ambulation

   Time frame: collected at baseline, discharge and at follow-up.

   Details about the ability of the patient to walk, cause of ambulation loss, use of an assistive device, and timing will be collected. 10 meter walk test (10 MWT) If the patient is able to ambulate without physical assistance (i.e. without help of a person), ambulation will be assessed by the 10MWT (walking aids are allowed). The 10MWT evaluates the time required to walk 10 meters. Patients should walk 10 meters with 2 meters for acceleration and deceleration. The patient will be timed from when the patient's toes of the leading foot cross the 2 meter line to when the patient's toes of the leading foot cross the 8 meter line. The test should be performed three times and the results will be averaged. The patient should be instructed to perform the test at a comfortable walking pace.

8. Nutritional status tool

   Time frame: collected at baseline, first prospective treatment, discharge and at follow-up.

   The Scored Patient-Generated Subjective Global Assessment (PG-SGA©) sets the standard of and is the preeminent interdisciplinary patient assessment (weight, intake, symptoms, functional status, disease state, metabolic stress and nutritional physical examination) in oncology and other chronic catabolic conditions. The Scored PG-SGA© includes the four patient-generated historical components ('Weight History', 'Food Intake', 'Symptoms' and 'Activities and Function'), the professional part (Diagnosis, Age, Metabolic stress, and Physical Exam), the Global Assessment (A = well nourished, B = moderately malnourished or suspected malnutrition, C = severely malnourished), the total numerical score, and nutritional triage recommendations. Subsequently, the Scored PG-SGA© allows for triaging of specific nutrition interventions, as well as facilitating quantitative outcomes data collection. This assessment is available in a variety of languages and as a metric as well as a non-metric version.

9. Morbidity data - Adverse events

   Time frame: collected at first prospective treatment, discharge and at follow-up.

   * related to surgery Intra- and postoperative complication data will be recorded for all surgically treated patients during the standard of care scheduled follow-up visits. Complications will be assessed by evaluating the patient's medical files from the time treatment was initiated until the day of follow-up. The Spine AdVerse Events Severity system, version 2 (SAVES V2) AE abstraction tool will be used to record the morbidity data. * related to radiation and/or systemic oncologic therapy For patients treated with RT and/or systemic oncologic therapy, complications and severity grade related to the treatment will be recorded during the standard of care scheduled follow-up visits according to a predefined list: The predefined list and severity grading system are according to the National Cancer Institute Guidelines.

10. Local disease recurrence data

    Time frame: collected at baseline and at follow-up.

    At every FU visit, each patient, regardless of which stage they are at in their treatment, will be evaluated for local disease control. Presence or absence of local control and distant metastases should be confirmed through imaging. The timing of the assessment will be performed in accordance with local standard of care scheduled FU visits.

11. Survival

    Time frame: collected at first prospective treatment, discharge and at follow-up.

    FU visits will be scheduled and performed according to the local standard of care and at each scheduled visit the patient's survival will be documented. In case a patient misses a scheduled visit it will be assessed if the patient is still alive.

12. Treatment details - Current treatment of the index target of the spine

    Time frame: collected at first prospective treatment and at follow-up.

    Since there is a spectrum of different treatment options and combinations for patients with a metastatic spine tumor, detailed information about the three main treatment options (surgery, radiation, and systemic oncologic therapy) for the index target will be collected. The treatment intent, including administration (primary, neo-adjuvant, and adjuvant) will also be collected.

13. Treatment details - Current treatment for the primary cancer

    Time frame: collected at baseline, first prospective treatment and at follow-up.

    Information on the status of the primary cancer as well as on ongoing treatment of the primary cancer will be collected at baseline and at follow-up.

14. Patient reported outcomes - Pain Numeric Rating Scale

    Time frame: collected at baseline, first prospective treatment, discharge and at follow-up.

    The Pain NRS is an 11-point scale where the end points are the extremes of no pain (0 points), or worst imaginable pain (10 points). It measures subjective intensity of pain and the patient rates his/her overall or average daily pain.

15. Patient reported outcomes - Spine Oncology Study Group Outcome Questionnaire (SOSGOQ)

    Time frame: collected at baseline, first prospective treatment, discharge and at follow-up.

    This is a new HRQOL outcome tool which was developed specifically for metastatic spine tumor. It is currently available in English and Hungarian. It contains 20 items representing all four domains of the International Classification of Function and Disability. Additionally there are seven follow-up questions referring to treatment satisfaction. It is made up of five domains: physical function, neural function, pain, mental health and social function. It was developed as a comparison to the SF-36 for patients with spine tumors.

Results and safety

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

Research links

• Official record on ClinicalTrials.govLast updated by the sponsor 6 Oct 2026.
• Individual participant dataSharing planned: No

Related trials for Metastatic Spine Tumor

• RecruitingPhase 3

  Stereotactic Body Radiotherapy vs Conventional Palliative Radiotherapy for Painful Non-Spine Bone Metastases

  Cancer Metastatic

• Active, not recruitingPhase 2

  Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord

  Malignant Digestive System Neoplasm, Metastatic Head and Neck Carcinoma

• Active, not recruitingPhase 2

  Cement Augmentation in Preventing Vertebral Body Compression Fracture Following Spine Stereotactic Radiosurgery in Patients With Solid Tumors and Spinal Metastases

  Metastatic Malignant Neoplasm in the Spine, Metastatic Malignant Solid Neoplasm

• Active, not recruitingPhase 1/2

  Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS)

  Spinal Neoplasms

• Active, not recruitingPhase 2

  Single Versus Multifraction Salvage Spine Stereotactic Radiosurgery for Previously Irradiated Spinal Metastases

  Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

24 sites in 10 countries: see every site and its status.